TransMedics Is Down 30% While Revenue Kept Compounding — the CFO Handoff Reads as Continuity, Not Distress

TransMedics just handed its finance chief job to Fernando Araujo, a twenty-year GE HealthCare veteran, effective September 21, and in the same breath restated its full-year 2026 revenue plan of $737 million to $757 million. A CFO swap is easy to skim past. What makes it worth lingering over is the backdrop: this is a company whose stock is down roughly 30% year to date and about 45% below its 52-week high, while the business underneath kept growing. The market is still paying for the old story. The question is whether the numbers have already changed to a new one.

For a reader new to the name, TransMedics sells the Organ Care System, a device that keeps donor organs alive outside the body — a beating heart, a ventilated lung — instead of packing them in ice. That warm-perfusion approach is bundled into a National OCS Program that pairs the hardware with its own logistics fleet of aircraft and clinical staffing, which is why the revenue looks like a hybrid of recurring product sales and higher-margin services. It is a real, commercial, roughly $600-million-a-year business, not a story stock waiting to happen.

The old story ran out of crayons

Rewind to what the market was pricing. TransMedics compounded hard through 2024 and 2025 — revenue rose about 37% to $605.5 million last year after nearly doubling the year before — and the shares ran to a $156 high. That is the euphoric version of the story, and it is what has deflated. The stock's fall is not random fear; it tracks a genuine shift in the financials, led by margins.

The clearest marker came in the first quarter of 2026, when the operating margin collapsed from about 19% a year earlier to below 8%, and it barely recovered in the second quarter, landing at 12.5%. The cause is not that revenue stopped growing — second-quarter revenue rose 21% year over year to a record $189.9 million — but that management is spending deliberately and heavily: research and development spending nearly doubled in the quarter, funding the next-generation platform, the kidney program, and clinical trials. Management took the rare step of cutting its own 2026 operating-margin guidance in half, to a 12.5%–14% range. Bears add customer concentration and trial delays to the list.

So the stock's pain has an honest foundation. This is not a case where the selloff happened for no reason. But the gap between the two halves of that sentence — revenue compounding near 20% while earnings guidance comes down — is exactly where the interesting question lives.

The part that makes the old story stale

The headlines here say margins hurt. The cash-flow path says something more interesting.

While operating earnings were being compressed by investment, the business was still converting sales into cash. Free cash flow over the trailing twelve months came to roughly $79 million, up more than 350% from a year earlier, a free-cash-flow margin in the mid-20% range. The balance sheet is not the constraint people fear: TransMedics ended June with about $473 million in cash, against debt that consists largely of 2028 convertible notes and financing tied to the aircraft fleet it buys for its logistics network. Management calls the plan self-funded.

The disciplined reading of that mix: the margin squeeze is a choice, not a deterioration. The company is deliberately spending down near-term profit to buy the next leg — a U.S. kidney market that involves more than 20,000 transplants a year and where the first clinical experience is targeted for 2027, an international expansion starting with Europe, and a next-generation platform. It reiterated the revenue plan of 22%–25% growth even while reshuffling its top finance role and cutting margin guidance. That is the tell: the operating script is unchanged.

That is what the CFO handoff actually signals. Araujo is not arriving to fix a broken finance function; he is arriving to scale a larger one, having run finance at a $16 billion segment of GE HealthCare. His predecessor, Gerardo Hernandez, is not leaving the company — he is moving to lead TransMedics' push into Latin America, which management describes as a materializing commercial opportunity. Read it as deepening the bench for a bigger role, not as distress.

Why it is not simply "buy the dip"

It would be comfortable to stop here and call the stock cheap. It is not, at least not yet. On a trailing basis the company trades for roughly 4–5 times sales and in the high-30s times trailing free cash flow — a reset from the euphoria, sure, but not a statistical bargain. And one caution on the earnings that look attractive: 2025 net income was flattered by an $82.8 million one-time tax benefit, so the low-looking trailing earnings multiple is partly an accounting artifact rather than genuine value.

The expectations reset is real, but incomplete. TransMedics is a bet on continued compounding — that revenue keeps growing near 20% while free cash flow expands and the invested dollars eventually show up in profit — not a cheap asset that re-rates by itself. That distinction is the whole ballgame.

What would prove the bull case wrong

That framing gives the thesis a shape you can test. The break condition is specific: revenue growth must hold somewhere near the guided 20%-plus, and free cash flow must keep rising even as capex and investment continue. If growth decelerates sharply or cash generation stalls while spending stays high, the case for a re-rating fails — the margin compression is then a real problem rather than a bridge.

The immediate tripwire is the current quarter. Management flagged that the third quarter is seasonally soft and that it intends to revisit the 2026 outlook when it reports those results, so the October print is the moment the plan either holds or wobbles. Between now and then, the single line of sight worth keeping is the free-cash-flow trajectory, not the daily quote. The market is still pricing the old risk profile while the operating setup is already getting cleaner. The numbers have not broken; they have just been temporarily pressed down by the deliberate cost of buying the next decade.